Combination treatment with ACY-738 can augment the anti-tumor efficacy of anti-PD-1 and anti-PD-L1 monoclonal antibodies in an Eμ-TCL1 adoptive transfer murine model by activating the cytotoxic CD8+ T-cell phenotype in chronic lymphocytic leukemia [97]. This evidence concerns the gene CD8A and neoplasm.